Symbicort is an inhaler used for long-term control of asthma and COPD, but it is not a rescue inhaler. Before using Symbicort, tell your healthcare provider if you have health conditions like adrenal ...

TITAN study results presented at CHEST meeting represent one of few asthma studies to examine African American patients exclusively SYMBICORT is a combination asthma medication that contains both an ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced the publication of data demonstrating that SYMBICORT Inhalation Aerosol 320/9 µg twice daily had a safety profile similar to ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Symbicort Turbuhaler contains two active ingredients in one inhaler: ...

DENVER--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced results from a long-term study comparing SYMBICORT ® (budesonide/ formoterol fumarate dihydrate) Inhalation Aerosol 160/4.5 mcg with ...

August 22, 2008 — A budesonide/formoterol (Symbicort, AstraZeneca) pressurized metered-dose inhaler (pMDI) showed safety and better asthma control versus budesonide alone, according to the results of ...

WILMINGTON, Del., June 2 /PRNewswire-FirstCall/ -- Today, the U.S. Food and Drug Administration (FDA) released final label revisions for respiratory medications that ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Symbicort Rapihaler contains two active ingredients in one inhaler: ...

Digital respiratory health company Propeller Health has received 510(k) clearance for a sensor and app intended for use with AstraZeneca's Symbicort inhaler for asthma and COPD, the company announced ...

AstraZeneca today announced that the European Patent Office (EPO) Technical Board of Appeal has made a final ruling that the European Combination patent covering the use of Symbicort (formoterol and ...

WILMINGTON, Del., Nov. 2, 2010 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that results from TITAN, a 12-week study of SYMBICORT® (budesonide ...

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) SYMBICORT is a combination asthma medication that contains both an inhaled corticosteroid (ICS ...